An Illustrated Look at Cronos Group Following their Q3 Earnings

As a follow up to our quick take this morning on Cronos Group (TSX: CRON, NASDAQ: CRON), we thought it would be helpful to share an illustrated look at Cronos Q3 earnings.

Cronos effectively doubled their cannabis output since Q2, selling 3,100 kg of dried gram cannabis equivalents. That’s about half of Aphria’s most recent quarterly unit sales and a sixth of Aurora’s.

Inventory is climbing steadily. The low BA total may represent the quarter’s end catching the grow rooms between cycles.
Cronos still lags other mid tier cultivators in unit sales…
…but they’re catching up

Yet, Cronos’ enterprise value is nearly identical to Aphria’s, and less than a third of Aurora’s. Whether this apparent value gap is tradeable is a matter of opinion, but few would argue with the notion that its roots are in Cronos’ financial position, relative to its peers, and in its backers.

Cronos has $1.92 billion in cash. That’s more than half of its market cap. The company carries no debt. The cash originated in the $2.4 billion equity investment made by US tobacco giant Altria this past December. Altria plans to use Cronos as its cannabis platform globally.

The tobacco business isn’t going anywhere and, more to the point, they have the background and understanding to make this particular type of consumer goods business work.

Cronos does not appear to be bothered by the fact that, among the unicorn-class Canadian cultivators, they have the smallest unit sales. Part of that is the strong growth, but it’s entirely possible that their US backers don’t expect this business to succeed as a Canadian cultivator. Altria may be content to use Canada as a sort of R&D lab. The retail footprint from their tobacco division can be considered a far better head start in the US market than all of the MSO front runners put together. From Altria’s perspective, the key to success in a US cannabis landscape that allows them to participate may well be the consumer product knowledge that they gain from their Cronos experiment.


Information for this analysis was found via Sedar and Cronos Group. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Mercado Minerals Identifies A Series Of New Targets Following LiDAR Survey At Copalito

Questcorp Launches Phase 2 Exploration Program At La Union To Follow Up On 20.2 g/t Gold Over 30 Metre Chip-Channel Sample

Related News

GameStop Reports 8.5% Drop in Revenue in Q3, with Substantial Adjusted EBITDA Loss; Valuation Remains Difficult to Understand

After the regular market close on December 7, GameStop Corp. (NYSE: GME) reported a second...

Sunday, December 11, 2022, 10:32:00 AM

Cronos Group Exits Its US Operations After Spending $300 Million To Acquire Them During Height Of Cannabis Bubble

Cronos Group (NASDAQ: CRON) announced on Wednesday that it will be closing down its existing US...

Thursday, June 1, 2023, 08:37:40 AM

Beyond Meat Faces Deeper Losses with Q4 Operating Deficit Swelling to $132.7 Million

Beyond Meat shares tumbled 9.71% to 63 cents in after-hours trading on Tuesday following a...

Tuesday, March 31, 2026, 05:12:01 PM

Cronos Group Receives Delinquency Letter From Nasdaq

Cronos Group (TSX: CRON) on Friday after hours provided a bi-weekly management cease trade update...

Monday, November 22, 2021, 08:52:45 AM

Cronos Group Posts Gross Margins Of 6% In Third Quarter

Cronos Group (TSX: CRON) this morning continued to demonstrate how not to run a cannabis...

Monday, November 7, 2022, 08:09:57 AM